MX392628B - Amortiguador de lavado de cromatografia de afinidad. - Google Patents
Amortiguador de lavado de cromatografia de afinidad.Info
- Publication number
- MX392628B MX392628B MX2019000898A MX2019000898A MX392628B MX 392628 B MX392628 B MX 392628B MX 2019000898 A MX2019000898 A MX 2019000898A MX 2019000898 A MX2019000898 A MX 2019000898A MX 392628 B MX392628 B MX 392628B
- Authority
- MX
- Mexico
- Prior art keywords
- wash buffer
- less
- affinity chromatography
- interest
- protein
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
- B01D15/424—Elution mode
- B01D15/426—Specific type of solvent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a un amortiguador de lavado que comprende arginina en una concentración mayor que 0 mM y menor que alrededor de 500 mM, guanidina en una concentración mayor que 0 mM y menor que alrededor de 250 mM, cloruro de sodio en una concentración mayor que 0 mM y menor que alrededor de 250 mM y un tensioactivo aniónico en una concentración mayor que 0 mM y menor que alrededor de 50 mM, o tensioactivo no iónico en una concentración mayor que 0 % y menor que alrededor de 0.25 %. Cuando se utiliza durante una purificación por cromatografía de afinidad de una proteína de interés, tal como un anticuerpo, el amortiguador de lavado reduce de manera significativa el nivel de proteínas de célula hospedadora de la preparación. Después de la cromatografía de afinidad con el amortiguador de lavado, la proteína de interés puede purificarse adicionalmente mediante el uso de cromatografía de membrana.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662366302P | 2016-07-25 | 2016-07-25 | |
| US201662366309P | 2016-07-25 | 2016-07-25 | |
| US201762523032P | 2017-06-21 | 2017-06-21 | |
| PCT/US2017/043743 WO2018022628A1 (en) | 2016-07-25 | 2017-07-25 | Affinity chromatography wash buffer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019000898A MX2019000898A (es) | 2019-07-01 |
| MX392628B true MX392628B (es) | 2025-03-24 |
Family
ID=60989729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000898A MX392628B (es) | 2016-07-25 | 2017-07-25 | Amortiguador de lavado de cromatografia de afinidad. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10688412B2 (es) |
| EP (1) | EP3487868B1 (es) |
| JP (1) | JP7187436B2 (es) |
| KR (1) | KR102359192B1 (es) |
| CA (1) | CA3031028C (es) |
| ES (1) | ES2994244T3 (es) |
| IL (1) | IL264123B (es) |
| MX (1) | MX392628B (es) |
| WO (1) | WO2018022628A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
| KR20240122922A (ko) | 2013-03-27 | 2024-08-13 | 세다르스-신나이 메디칼 센터 | Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전 |
| EP4105236A1 (en) | 2013-07-19 | 2022-12-21 | Cedars-Sinai Medical Center | Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease |
| CN109462996A (zh) | 2016-03-17 | 2019-03-12 | 西达-赛奈医疗中心 | 通过rnaset2诊断炎性肠病的方法 |
| CN110121509B (zh) | 2016-10-26 | 2024-05-07 | 西达-赛奈医疗中心 | 中和抗tl1a单克隆抗体 |
| WO2018237159A1 (en) | 2017-06-21 | 2018-12-27 | Cephalon, Inc. | Cation exchange chromatography wash buffer |
| MA52366A (fr) | 2018-04-25 | 2021-03-03 | Prometheus Biosciences Inc | Anticorps anti-tl1a optimisés |
| EP4047006A4 (en) * | 2019-10-17 | 2023-11-01 | JCR Pharmaceuticals Co., Ltd. | Method for producing fusion protein of serum albumin and growth hormone |
| PH12022550978A1 (en) | 2019-10-24 | 2023-10-09 | Cedars Sinai Medical Center | Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof |
| KR20220130692A (ko) * | 2020-01-20 | 2022-09-27 | 우시 바이올로직스 아일랜드 리미티드 | 친화성 크로마토그래피를 위한 신규한 세척 완충제 용액 |
| MX2022011780A (es) * | 2020-04-09 | 2022-11-10 | Cytomx Therapeutics Inc | Composiciones que contienen anticuerpos activables. |
| US20230143163A1 (en) * | 2020-04-27 | 2023-05-11 | Alexion Pharmaceuticals, Inc. | Protein a chromatography purification of an antibody |
| CN116348486A (zh) * | 2020-10-02 | 2023-06-27 | 伊莱利利公司 | 在蛋白质纯化过程中降低宿主细胞蛋白质含量的方法 |
| CN112827217A (zh) * | 2020-12-29 | 2021-05-25 | 苏州良辰生物医药科技有限公司 | 一种层析柱清洗液及其应用 |
| WO2024143439A1 (ja) * | 2022-12-28 | 2024-07-04 | 富士フイルム株式会社 | 再生された担体の製造方法、洗浄液、キット、及び、細胞外小胞の製造方法 |
| CN116236819B (zh) * | 2023-05-09 | 2023-08-04 | 成都佩德生物医药有限公司 | 一种批量纯化多肽毒素的方法及复合型双层层析柱 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4672044A (en) | 1984-08-24 | 1987-06-09 | Scripps Clinic & Research Foundation | Murine monoclonal antibody combining site to human C3b receptor (CR1) |
| JPH01238534A (ja) * | 1988-03-17 | 1989-09-22 | Mitsui Toatsu Chem Inc | エンドトキシンの除去方法 |
| DE68924850T2 (de) * | 1988-06-14 | 1996-10-10 | Cell Med Inc | Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren. |
| GB9022547D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Purified immunoglobulin |
| US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| US6531577B1 (en) | 1997-12-15 | 2003-03-11 | Hemasure Denmark A/S | von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations |
| GB0304576D0 (en) | 2003-02-28 | 2003-04-02 | Lonza Biologics Plc | Protein a chromatography |
| EP1614693A4 (en) | 2003-03-31 | 2006-07-19 | Kirin Brewery | Purification of a human monoclonal antibody and human polyclonal antibody |
| WO2005051994A2 (en) | 2003-11-21 | 2005-06-09 | Zymogenetics, Inc. | Ztnf11, a tumor necrosis factor |
| US8084032B2 (en) | 2004-01-21 | 2011-12-27 | Ajinomoto Co., Inc. | Purification method which prevents denaturation of an antibody |
| WO2006023420A2 (en) | 2004-08-16 | 2006-03-02 | Medimmune, Inc. | Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity |
| EP1685161A1 (en) | 2004-08-30 | 2006-08-02 | Lonza Biologics plc | Affinity- plus ion exchange-chromatography for purifying antibodies |
| WO2006099308A2 (en) | 2005-03-11 | 2006-09-21 | Wyeth | A method of weak partitioning chromatography |
| JP5123197B2 (ja) * | 2005-11-14 | 2013-01-16 | ライナット ニューロサイエンス コーポレイション | カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体およびその使用方法 |
| CN102626610B (zh) | 2006-01-06 | 2014-10-01 | Emd密理博公司 | 亲和层析基质及其制备和使用方法 |
| CL2007002615A1 (es) | 2006-09-08 | 2008-04-18 | Wyeth Corp | Metodos para aislar o purificar un producto que comprende poner el producto enlazado en contacto con al menos una solucion de lavado que comprende arginina y luego eluir el producto; y dicho producto. |
| WO2009025300A1 (ja) | 2007-08-21 | 2009-02-26 | Regenetiss Inc. | イミュノグロブリン結合能を有するペプチド |
| US20090162372A1 (en) | 2007-11-30 | 2009-06-25 | Medarex, Inc. | Fibronectin ed-b antibodies, conjugates thereof, and methods of use |
| JP5504579B2 (ja) | 2008-05-12 | 2014-05-28 | 積水ハウス株式会社 | 住宅の床着脱構造及び住宅の改装方法 |
| CA2726823A1 (en) | 2008-06-03 | 2009-12-10 | Patrys Limited | Process for purification of antibodies |
| AU2009282234A1 (en) | 2008-08-14 | 2010-02-18 | Merck Sharp & Dohme Corp. | Methods for purifying antibodies using protein a affinity chromatography |
| LT3750552T (lt) | 2008-08-14 | 2023-06-26 | Acceleron Pharma Inc. | Gdf gaudyklės |
| KR20110079693A (ko) | 2008-10-29 | 2011-07-07 | 와이어쓰 엘엘씨 | 단일 도메인 항원 결합 분자의 정제 방법 |
| WO2010062401A2 (en) | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules |
| EP2360183B1 (en) | 2008-12-19 | 2016-07-27 | Takeda Pharmaceutical Company Limited | Antibody purification method by mixed mode chromatography utilizing an arginine-containing loading solution |
| US20110306554A1 (en) | 2009-01-23 | 2011-12-15 | Osamu Masaki | Peptide capable of binding to immunoglobulin |
| CA2784278C (en) * | 2009-12-18 | 2019-02-26 | Novartis Ag | Wash solution and method for affinity chromatography |
| EP3266793A1 (en) | 2010-06-21 | 2018-01-10 | Kyowa Hakko Kirin Co., Ltd. | Method for purifying protein using amino acid |
| AU2012315474B2 (en) * | 2011-09-30 | 2017-10-26 | Teva Pharmaceuticals Australia Pty Ltd. | Antibodies against TL1a and uses thereof |
| FI3677591T3 (fi) * | 2013-04-29 | 2023-04-03 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd38-vasta-aineet ja fuusiot heikennetylle interferonille alfa-2b |
| SG10201802525QA (en) * | 2013-09-13 | 2018-04-27 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides |
| US10941178B2 (en) | 2017-03-17 | 2021-03-09 | Gilead Sciences, Inc. | Method of purifying an antibody |
| WO2018237159A1 (en) * | 2017-06-21 | 2018-12-27 | Cephalon, Inc. | Cation exchange chromatography wash buffer |
-
2017
- 2017-07-25 MX MX2019000898A patent/MX392628B/es unknown
- 2017-07-25 ES ES17835124T patent/ES2994244T3/es active Active
- 2017-07-25 KR KR1020197002710A patent/KR102359192B1/ko active Active
- 2017-07-25 EP EP17835124.3A patent/EP3487868B1/en active Active
- 2017-07-25 WO PCT/US2017/043743 patent/WO2018022628A1/en not_active Ceased
- 2017-07-25 JP JP2019503524A patent/JP7187436B2/ja active Active
- 2017-07-25 CA CA3031028A patent/CA3031028C/en active Active
- 2017-07-25 US US15/659,093 patent/US10688412B2/en active Active
-
2019
- 2019-01-07 IL IL264123A patent/IL264123B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| IL264123A (en) | 2019-02-28 |
| ES2994244T3 (en) | 2025-01-21 |
| EP3487868A1 (en) | 2019-05-29 |
| MX2019000898A (es) | 2019-07-01 |
| KR20190032394A (ko) | 2019-03-27 |
| JP7187436B2 (ja) | 2022-12-12 |
| EP3487868A4 (en) | 2020-07-29 |
| EP3487868B1 (en) | 2024-08-28 |
| IL264123B (en) | 2021-03-25 |
| WO2018022628A1 (en) | 2018-02-01 |
| JP2019525925A (ja) | 2019-09-12 |
| CA3031028C (en) | 2024-02-13 |
| US10688412B2 (en) | 2020-06-23 |
| US20180021696A1 (en) | 2018-01-25 |
| CA3031028A1 (en) | 2018-02-01 |
| KR102359192B1 (ko) | 2022-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX392628B (es) | Amortiguador de lavado de cromatografia de afinidad. | |
| MX2019015304A (es) | Amortiguador de lavado para cromatografia de intercambio cationico. | |
| MX2020004578A (es) | Composiciones de casz y metodos de uso. | |
| MX2022012042A (es) | Composiciones de proteina anti-vegf y metodos para producir la misma. | |
| MX2021003475A (es) | Metodos de purificacion de proteinas. | |
| MX395730B (es) | Uso de lavados alcalinos durante la cromatografia para remover impurezas. | |
| EA201691111A1 (ru) | Химерные белки фактора viii и их применение | |
| EP4442816A3 (en) | Mutated glycoprotein of vesicular stomatitis virus | |
| EA201892671A1 (ru) | Пегилированный свиной интерферон и способы его применения | |
| MX383614B (es) | Proteinas de union triespecificas y metodos de uso. | |
| UA124343C2 (uk) | Капсиди аденоасоційованого вірусу і спосіб його використання | |
| BR112017015567A2 (pt) | proteína gl de citomegalovírus recombinante ou fragmento de formação de complexo da mesma, complexo de citomegalovírus, ácido nucleico isolado, célula hospedeira, e, composição imunogênica | |
| MX383537B (es) | Mutantes de proteína f de rsv. | |
| BR112018068189A2 (pt) | proteínas de ligação induzíveis e métodos de uso | |
| EP4389757A3 (en) | Methods for purifying antibodies | |
| BR112018001572A2 (pt) | método para induzir uma resposta imune, antígeno, adenovírus, uso de um antígeno e de um adenovírus, e, polinucleotídeo. | |
| EP3543335A3 (en) | Soluble intein fusion proteins and methods for purifying biomolecules | |
| MX389093B (es) | Composiciones y metodos para la glicosilacion de proteinas. | |
| MX2016017115A (es) | Metodos y reactivos para la purificacion de proteinas. | |
| EA201491643A1 (ru) | Идентификация мутаций канал-опсина-2 (chop2) и способы применения | |
| GEP20207139B (en) | Liquid neurotoxin formulation stabilized with tryptophan or tyrosine | |
| BR112017017609A2 (pt) | proteína de fusão fc, e, composição farmacêutica. | |
| MX2024010249A (es) | Metodos para potenciar la eliminacion de impurezas durante una cromatografia con proteina a. | |
| CL2017000200A1 (es) | Célula huésped mejorada para producir proteinas | |
| MX2020000018A (es) | Potencializacion de componentes sanguineos de actividad anti-bacteriana de proteina litica y metodos y usos de estos. |